{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:11:48Z","timestamp":1769742708653,"version":"3.49.0"},"reference-count":18,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,1,25]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Anaplastic large cell lymphoma (ALCL), ALK negative (ALK\u2212) is an aggressive lymphoproliferative disorder of mature T lymphocytes characterised by hallmark cells, CD30 positivity and lacking ALK protein expression. ALCL, ALK\u2212 has to be differentiated from peripheral T-cell lymphoma-not otherwise specified and classical Hodgkin\u2019s lymphoma. ALK\u2212 anaplastic large cell leukaemia should be considered in a patient with a history of ALCL, ALK\u2212 presenting with new leukaemia. We report a rare presentation of relapsed ALCL, ALK\u2212 with leukaemia after autologous stem cell transplantation in a 57-year-old male. Leukaemia, either as primary presentation or secondary transformation confers worse prognosis in ALCL, ALK\u2212 with very few cases reported so far. Emergency resuscitation with leukapheresis and treatment of tumour lysis syndrome along with supportive care should be followed by combination chemotherapy. Brentuximab vedotin and stem cell transplantation are the backbone of treatment for relapsed\/refractory disease.<\/jats:p>","DOI":"10.1136\/bcr-2020-239213","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:36:12Z","timestamp":1613993772000},"page":"e239213","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Leukaemic relapse of anaplastic large cell lymphoma, ALK negative"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6449-8109","authenticated-orcid":false,"given":"Nabin Raj","family":"Karki","sequence":"first","affiliation":[{"name":"Hematology Oncology, Augusta University, Augusta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Badin","sequence":"additional","affiliation":[{"name":"Jersey City Medical Center, Jersey City, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Savage","sequence":"additional","affiliation":[{"name":"Pathology, Augusta University, Augusta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Locke","family":"Bryan","sequence":"additional","affiliation":[{"name":"Hematology Oncology, Augusta University, Augusta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"2025082713170820000_14.2.e239213.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2025082713170820000_14.2.e239213.2","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.18632\/oncotarget.14503","article-title":"The heterogeneous landscape of ALK negative ALCL","volume":"8","author":"Mereu","year":"2017","journal-title":"Oncotarget"},{"key":"2025082713170820000_14.2.e239213.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.06.004"},{"key":"2025082713170820000_14.2.e239213.4","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"key":"2025082713170820000_14.2.e239213.5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20359"},{"key":"2025082713170820000_14.2.e239213.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.07.034"},{"key":"2025082713170820000_14.2.e239213.7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3109\/10428194.2010.502585","article-title":"ALK-negative anaplastic large cell lymphoma in leukemic phase with near-pentaploidy","volume":"51","author":"Wong","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2025082713170820000_14.2.e239213.8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2169\/internalmedicine.51.6146","article-title":"Leukemic presentation of ALK-negative anaplastic large cell lymphoma in a patient with myelodysplastic syndrome","volume":"51","author":"Tanaka","year":"2012","journal-title":"Intern Med"},{"key":"2025082713170820000_14.2.e239213.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"2025082713170820000_14.2.e239213.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.006"},{"key":"2025082713170820000_14.2.e239213.11","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"2025082713170820000_14.2.e239213.12","first-page":"45","article-title":"Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin","volume":"7","author":"Chen","year":"2013","journal-title":"Onco Targets Ther"},{"key":"2025082713170820000_14.2.e239213.13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"The Lancet"},{"key":"2025082713170820000_14.2.e239213.14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.213512"},{"key":"2025082713170820000_14.2.e239213.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4785"},{"key":"2025082713170820000_14.2.e239213.16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12308-018-0318-2","article-title":"Leukemic phase of primary cutaneous anaplastic large-cell lymphoma (ALK-negative), with downregulation of CD30","volume":"11","author":"Glynn","year":"2018","journal-title":"J Hematop"},{"key":"2025082713170820000_14.2.e239213.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091"},{"key":"2025082713170820000_14.2.e239213.18","unstructured":"Changlee S , Pang ACH . ALK-negative anaplastic large cell lymphoma, leukemic phase [Internet]. Available: https:\/\/imagebank.hematology.org\/image\/17922\/alknegative-anaplastic-large-cell-lymphoma-leukemic-phase [Accessed 7 Jul 2019]."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-239213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:17:15Z","timestamp":1756325835000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-239213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,22]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bcr-2020-239213"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-239213","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}